Trevena, Inc. (NASDAQ:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the quarter ended March 31, 2014.
“We have had a strong start to 2014, reflecting continued investment in our novel pipeline of biased ligands targeting validated GPCRs,” stated Maxine Gowen, Ph.D., chief executive officer of Trevena.
Help employers find you! Check out all the jobs and post your resume.
